Beaver Run Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2018



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Cancer Epigenetics: New Mechanisms, New Therapies (B4)


Organizer(s) François Fuks and Anne Brunet
February 10—14, 2018
Beaver Run Resort • Breckenridge, Colorado USA
Discounted Abstract Deadline: Oct 10, 2017
Abstract Deadline: Nov 8, 2017
Scholarship Deadline: Oct 10, 2017
Discounted Registration Deadline: Dec 12, 2017

Sponsored by Cancer Research UK, Cell Research, Incyte Corporation, Merck & Co., Inc., Novartis Institutes for BioMedical Research, Pfizer Inc. and Roche

Summary of Meeting:
The field of epigenetics has recently emerged as an essential component of oncology research, with altered epigenetic modifications considered to be critical hallmarks of cancers. Unlike mutations, epigenetic aberrations are reversible and as a result, epigenetic therapies hold great promise as anti-cancer agents. For these novel therapies to succeed, a key challenge is to fully understand the nature and the mechanisms that lead to epigenetic changes in cancer. Another essential challenge is to make sense of the avalanche of data flowing from increasingly powerful "omics-based" technologies. Despite these challenges, never has the potential for scientific and clinical breakthroughs in this field been greater. Bringing together both the academic and the pharmaceutical communities, this Keystone Symposia conference will focus on: 1) The newest findings concerning the mechanisms by which epigenetic pathways are established and maintained in normal and stem cells, and how these go awry during aging and cancer, with a special emphasis on histone modifications, chromatin remodeling and the unexpected increased number of DNA modifications ((hydroxy)methylcytosine and methyladenine); 2) The growing roles of noncoding RNAs in cancer and the emergence of the new and exciting realm of RNA epigenetics; 3) Use of new omics technologies to interrogate altered epigenetic landscapes in tumors and assess their clinical implications; and 4) Novel and promising therapeutic drugs aimed at reversing specific epigenetic alterations. Ultimately, the meeting will provide great opportunities for senior and junior scientists to meet the leaders in the field from both academia and industry, hence forging exciting interdisciplinary interactions and creating potential new collaborations in the burgeoning area of cancer epigenetics.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Saturday, February 10 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Wednesday, February 14 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Thursday, February 15 in order to fully experience the meeting.

SATURDAY, FEBRUARY 10

16:00—20:00
Arrival and Registration

Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Foyer

SUNDAY, FEBRUARY 11

07:00—08:00
Breakfast

Summit Gallery
08:00—09:00
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* François Fuks, Université libre de Bruxelles, Belgium

* Anne Brunet, Stanford University, USA

Tony Kouzarides, University of Cambridge, UK
Modifications of RNA: Their Function and Role in Cancer

09:00—11:30
Epigenetic Mechanisms and Cancer
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Anne Brunet, Stanford University, USA

Geneviève Almouzni, Centre National de la Recherche Scientifique, France
Chromatin Determinants of Centromeric Identity and their Deregulation in Cancer

Adrian P. Bracken, Trinity College Dublin, Ireland
Short Talk: A New Family of Vertebrate-Specific Polycombs Balance PRC2 Subtype Activities

Coffee Break

François Fuks, Université libre de Bruxelles, Belgium
Transcriptome-Wide Distribution and Function of RNA Modifications in Cancer

Panagiotis Ntziachristos, Northwestern University, USA
Short Talk: Active Deubiquitination as a Molecular Rheostat Controlling Resistance to Therapy in Acute Leukemia

Shelley L. Berger, University of Pennsylvania, USA
Epigenetic Pathways as Targets in Human Cancer

11:30—17:00
On Own for Lunch

11:30—13:00
Poster Setup

Breckenridge Ballroom
13:00—22:00
Poster Viewing

Breckenridge Ballroom
16:30—17:00
Coffee Available

Foyer
17:00—19:30
Chromatin Dysregulations in Cancer
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Johnathan R. Whetstine, Massachusetts General Hospital, USA

Luciano Di Croce, CRG - Center for Genomic Regulation, Spain
Role of Polycomb and MLL Complexes in Nuclear Architecture and Gene Regulation

Cigall Kadoch, Dana-Farber Cancer Institute, Harvard Medical School, USA
BAF Complex Structure and Function in Human Cancer

Tom Owen-Hughes, University of Dundee, Scotland
Short Talk: Variation in the Protein Composition of SWI/SNF Chromatin Remodeling Complexes in Clear Cell Renal Carcinoma

Ozgur Oksuz, New York University School of Medicine, USA
Capturing the Onset of Polycomb Domain Formation

William J. Greenleaf, Stanford University, USA
ATAC-ing Gene Regulation in Cancer and Development

19:30—20:30
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom
19:30—22:00
Poster Session 1

Breckenridge Ballroom

MONDAY, FEBRUARY 12

07:00—08:00
Breakfast

Summit Gallery
08:00—11:15
Emergence of Epitranscriptomics
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Cigall Kadoch, Dana-Farber Cancer Institute, Harvard Medical School, USA

Lu Wang, Northwestern University, USA
Resetting the Epigenetic Balance of Polycomb/COMPASS Function for Cancer Therapy

Chuan He, University of Chicago, USA
Aberrant RNA Methylation in Human Cancers

Ulrike Litzenburger, Stanford University, USA
Short Talk: Direct Linkage of Cancer Cell Epigenomic State with Phenotype using Multi-Index Single-Cell ATAC-Seq

Coffee Break

Gideon Rechavi, Tel Aviv University, Israel
Cancer Epitranscriptomics

Brian J. Abraham, Whitehead Institute, USA
Short Talk: Three-Dimensional Gene Regulatory Landscapes in Normal and Cancer Cells

Gerald R. Crabtree, Stanford University, USA
Pathogenic Mechanisms in the Opposition of BAF(mSWI/SNF) and Polycomb in Human Cancer

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Breckenridge Ballroom
13:00—22:00
Poster Viewing

Breckenridge Ballroom
16:30—17:00
Coffee Available

Foyer
17:00—19:00
Chromatin Assembly, Stem Cells and Aging
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Karen Adelman, Harvard Medical School, USA

Robert E. Kingston, Massachusetts General Hospital, USA
Nucleosome Compaction and Polycomb-Group Repressive Function during Development

Johnathan R. Whetstine, Massachusetts General Hospital, USA
Epigenetics as a Gatekeeper to DNA Amplification

Ernesto Guccione, Institute of Molecular and Cell Biology, Singapore
Short Talk: Investigating the Function of PRDM Proteins in Stem Cells and Cancer

Anne Brunet, Stanford University, USA
Epigenetic and Metabolic Regulation of Aging and Rejuvenation

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom
19:30—22:00
Poster Session 2

Breckenridge Ballroom

TUESDAY, FEBRUARY 13

07:00—08:00
Breakfast

Summit Gallery
08:00—11:15
DNA (de)Methylation Dynamics and Cancer
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Kornelia Polyak, Dana-Farber Cancer Institute, Harvard Medical School, USA

Stephen B. Baylin, Johns Hopkins University School of Medicine, USA
DNA Methylation in Stem Cell and Cancer

Luisa Cimmino, New York University, USA
Short Talk: Restoration of TET Function as a Therapeutic Strategy in Leukemia

Peter A. Jones, Van Andel Research Institute, USA
Targeting Endogenous Retroviruses for Therapy

Coffee Break

Salvador Aznar Benitah, ICREA and Institute for Research in Biomedicine, Spain
Epigenetic Mechanisms in Adult Stem Cell Function, and their Impact over Mutational Burden of Cancer Stem Cells

Timothy C. Hallstrom, University of Minnesota, USA
Short Talk: UHRF2 Control of 5hmC Homeostasis and Differentiation in Retinal Progenitor Cells

Karen Adelman, Harvard Medical School, USA
Probing Transcription Regulation at Enhancers

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Breckenridge Ballroom
13:00—22:00
Poster Viewing

Breckenridge Ballroom
16:30—17:00
Coffee Available

Foyer
17:00—19:00
Connecting Noncoding RNAs and Cancer
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Salvador Aznar Benitah, ICREA and Institute for Research in Biomedicine, Spain

John L. Rinn, University of Colorado Boulder, USA
A Conserved TAD Boundary Organization at the Firre lncRNA Locus Is Resistant to Loss of Numerous CTCF Binding Sites

Chris Marine, VIB-KU Leuven, Belgium
(Patho-)Physiological Functions of the lncRNA NEAT1

Yotam Drier, MGH and Harvard Medical School, USA
Short Talk: Epigenetic Inhibition of CTCF Insulation in Cancer

Robert A. Martienssen, Cold Spring Harbor Laboratory, USA
Replication-Coupled Silencing and Spreading with RNAi

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom
19:30—22:00
Poster Session 3

Breckenridge Ballroom

WEDNESDAY, FEBRUARY 14

07:00—08:00
Breakfast

Summit Gallery
08:00—11:15
Novel Therapeutic Discoveries in Epigenetics I
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* John L. Rinn, University of Colorado Boulder, USA

Mark A. Dawson, Peter MacCallum Cancer Centre, Australia
Molecular Mechanisms Governing Sensitivity and Resistance to Epigenetic Therapies

Danette L. Daniels, Promega Corporation, USA
Short Talk: Understanding the Functional Pathway of BET Family Degradation Compounds

Kornelia Polyak, Dana-Farber Cancer Institute, Harvard Medical School, USA
KDM5B Links Cellular Transcriptome Heterogeneity to Therapy Resistance

Coffee Break

Robert MacLeod, Ionis Pharmaceuticals, Inc., USA
Next Generation Antisense Oligonucleotides as Therapeutic Inhibitors of LncRNAs for the Treatment of Cancer

Allison E. Drew, Epizyme, USA
Short Talk: Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma

Ronan C. O'Hagan, Merck Research Laboratories, USA
Epigenetics and Immune Modulation in Cancer

11:15—17:00
On Own for Lunch

14:00—16:30
Workshop: Epigenetic Pathways and Cancer

Colorado Ballroom
* Tom Owen-Hughes, University of Dundee, Scotland

Giovanni Ciriello, University of Lausanne, Switzerland
The Landscape of Aberrant DNA Methylation across Human Cancers

Robert M. Witwicki, Dana-Farber Cancer Institute, USA
Novel Epigenetic Dependencies of Human Cancers

Noa Furth, Weizmann Institute of Science, Israel
Rewiring of Tumor Suppressors Networks: LATS Kinases and p53

Sandra Schick, CeMM GmbH, Austria
Loss of Specific Mammalian BAF Subunits Causes Global Changes in Chromatin Accessibility

Molly Christine Kingsley, University of Colorado, USA
The Role of H3K79 Methylation in IDH Mutant AML

Elisa Oricchio, École Polytechnique Fédérale de Lausanne, Switzerland
Oncogenic Mutation of EZH2 Inactivates Tumor- Suppressive TADs to Promote Lymphomagenesis

David I. Remillard, Harvard University, USA
Targeted Degradation of BRD9 as a Therapeutic Strategy in BAF-Dependent Cancers

Lingyan Jin, Genentech, Inc., USA
Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer

Beth Zucconi, Harvard Medical School, USA
Modulation of p300/CBP Activity by Small Molecules

16:30—17:00
Coffee Available

Foyer
17:00—18:45
Novel Therapeutic Discoveries in Epigenetics II
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Mark A. Dawson, Peter MacCallum Cancer Centre, Australia

Myriem Boufraqech, NCI, National Institutes of Health, USA
Targeting the Epigenome in Endocrine Cancers

Rab K. Prinjha, GlaxoSmithKline, UK
Epigenetic Targets for the Treatment of Human Diseases

James E. Bradner, Novartis Institutes for BioMedical Research, USA
Targeted Degradation of Chromatin-Associated Transcription Factors

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Breckenridge Ballroom

THURSDAY, FEBRUARY 15

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Cancer Research UK Cell Research
Incyte Corporation Merck & Co., Inc.
Novartis Institutes for BioMedical Research Pfizer Inc.
Roche
 

We gratefully acknowledge additional support from these exhibitors at this conference:

EpiCypher
Please stop by to meet these exhibitors during the conference.


We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1 R13 CA224772-01

Funding for this conference was made possible (in part) by 1 R13 CA224772-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional support for this conference from:

Abcam plc

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Ionis Pharmaceuticals, Inc.


Merck & Co., Inc.


Novartis Institutes for BioMedical Research


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676